Drug delivery

Dr Jason Bellia, Senior Patent Examiner at the UK Intellectual Property Office (IPO) I will look at just two of a vast number of routes - one to deliver nucleic acids across cell membranes and another looking...

Compulsory licensing of pharmaceuticals: A solution to high drug prices?

The UK continues to grapple with its departure – or not – from the European Union, and whilst the outcome remains unclear, one thing now seems certain: before long there will be a general...

UK Supreme Court inflicts more patent pain on Warner-Lambert

Eilidh Pugh, Pharmaceutical Patent Attorney, AdamsonJones. The UK Supreme Court has handed down its much-anticipated decision in WarnerLambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis. The case is important because it is the...

Patent Protection of Medical Devices – Time for a Rethink?

Christopher Burnett,  Patent Attorney,  AA Thornton The duration of patent protection for medical devices is up to twenty years, as for any other type of device. Pharmaceuticals, on the other hand, may be entitled to an...

The Nagoya Protocol and the UK – Are you Compliant?

The Nagoya Protocol has been in force in the UK since October 2015 and obliges users of genetic resources and traditional knowledge associated with genetic resources to comply with due diligence requirements before its...

Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...

Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...

Creating a Corona Vaccine

Varuni Paranavitane, IP Solicitor,  AA Thornton. As the world faces unprecedented challenges caused by the SARS-Cov-2 virus, we look at the science behind vaccine technology being investigated and how intellectual property rights may play a part...

UK offers accelerated patent protection for eco-friendly innovations

Using the Green Channel to accelerate a UK patent application. AdamsonJones was able to obtain patent protection for client, LLEO Ltd, in just 15 months from the moment the Green Channel was used. This acceleration was crucial as...

The importance of Intellectual Property strategy; creating a foundation on which to build value...

Dr Emma Longland and Craig Thomson of HGF writing for the Chartered Institute of Patent Attorneys Most companies in the Biotech space appreciate the need for patent protection; after all, no company wants to bring...

Is your IP Strategy fit for purpose? – Five Questions to Ask Yourself

As a result of the lockdown due to the global pandemic there is a greater need and renewed focus on using innovation to kick-start the economic recovery. The result is significant investment in R&D...

EU-wide IP Expertise is essential to the life science industry post-Brexit

The UK is world-renowned for its progressive life science and healthcare sectors, which are at the forefront of technical innovation, research excellence, and pioneering treatments. Life science companies, research and development facilities, scientists and academics...

Biosimilars and Patents

Leonita Paulraj - Associate, AA Thornton The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of)...

Shanks v Unilever – An opening of the claim floodgates?

Varuni Paranavitane, IP Solicitor,  AA Thornton At the end of last year Professor Shanks was awarded £2 million for an invention relating to a glucose sensor made while employed working for Unilever.  What does this mean...

Protecting Digital Medtech Innovation

For many years the medical technology (medtech) sector has been at the forefront of innovation and the Covid-19 pandemic has not slowed it down, with new technology quickly being developed to test for, prevent...

Know your third party patent rights

In the competitive world of the biosciences, third party patent rights (TPRs) can stand in the way of a planned course of action, even after significant investment has been made. Knowledge of such rights...

The IP journey and risk mitigation

Paul Storer Senior Policy Adviser in the Business Support Policy Team at the IPO Resolving IP disputes can be costly and the Intellectual Property Office continues to seek to reduce costs for businesses, not only in...